A5047257257- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Hematopoietic Stem Cell Transplantation
- Immune Cell Function and Interaction
- Glycosylation and Glycoproteins Research
- Viral-associated cancers and disorders
- Protein Degradation and Inhibitors
- T-cell and B-cell Immunology
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Hematological disorders and diagnostics
- Proteoglycans and glycosaminoglycans research
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Ubiquitin and proteasome pathways
- T-cell and Retrovirus Studies
- Immunodeficiency and Autoimmune Disorders
- Inflammasome and immune disorders
- Acute Lymphoblastic Leukemia research
- SARS-CoV-2 and COVID-19 Research
- Cytokine Signaling Pathways and Interactions
Université de Montpellier
2010-2024
Institut Sainte Catherine
2019-2024
Centre Hospitalier Universitaire de Montpellier
2007-2022
Institute for Regenerative Medicine & Biotherapy
2006-2022
Hôpital Saint Eloi
1998-2020
Inserm
2004-2015
Hôpital Lapeyronie
2002-2012
Neuropsychiatrie : Recherche Epidemiologique et Clinique
2009
University Hospital Heidelberg
2006
Gene Therapy Laboratory
2006
We investigated the possible causative role of interleukin 6 (IL-6) in paraneoplastic inflammatory syndrome and cholestasis (Stauffer syndrome) associated with renal-cell carcinoma a series 119 patients metastases. IL-6 levels were found significantly higher fever weight loss. Patients detectable serum (n = 90, 76%) had CRP, haptoglobin, alkaline-phosphatase gammaglutamyl-transferase levels. Platelets, polymorphonuclear neutrophil (PMN) monocyte counts also IL-6; contrast, hemoglobin lower...
PURPOSE To compare progression-free survival (PFS), overall (OS), and toxicity of a doxorubicin-containing regimen administered alone or in combination with interferon alfa-2b (IFNalpha) patients low-grade follicular lymphoma (FL) poor prognostic factors. PATIENTS AND METHODS Two hundred sixty-eight advanced-stage FL received cyclophosphamide, doxorubicin, teniposide, prednisone (CHVP) monthly for 6 months, then every 2 months 12 months. After randomization, 242 were evaluated efficacy: 119...
Proliferation of malignant plasma cells is a strong adverse prognostic factor in multiple myeloma and simultaneously targetable by available (e.g. tubulin polymerase inhibitors) upcoming aurora kinase compounds.We assessed proliferation using gene expression-based indices 757 samples including independent cohorts 298 345 CD138-purified from previously untreated patients undergoing high-dose chemotherapy, together with clinical factors, chromosomal aberrations, high-risk scores.In the two...
PURPOSE: Subcutaneous recombinant interleukin-2 (rIL-2) and interferon alfa-2a (rIFNα-2a) have been used extensively in the treatment of metastatic renal cancer. Most results, coming from noncontrolled phase II trials, showed inconsistent rates response. More recently, addition fluorouracil (FU) was proposed to improve efficacy these regimens. PATIENTS AND METHODS: The role a subcutaneous combination rIL-2 rIFNα-2a with or without FU investigated. Patients were randomly assigned receive at...
Abstract Cancer-testis (CT) Ags are expressed in testis and malignant tumors but rarely nongametogenic tissues. Due to this pattern, they represent attractive targets for cancer vaccination approaches. The aims of the present study are: 1) assess expression CT genes on a pangenomic base multiple myeloma (MM); 2) prognosis value gene expression; 3) provide selection strategies clinical trials. We report pattern purified MM cells (MMC) 64 patients with newly diagnosed and12 monoclonal...
Purpose We hypothesized that granulocyte-macrophage colony-stimulating factor (GM-CSF) could potentiate the clinical activity of rituximab given its individual and cooperative effects on FcγRIIa- FcγRIIIa-expressing cells. A phase II study combining GM-CSF was initiated in patients with relapsed follicular lymphoma (FL) to determine biologic responses, as well safety combination. Patients Methods Thirty three FL were treated 5 μg/kg/d days 1 8 375 mg/m 2 day each 21-day cycle for four...
The leucocyte-specific phosphatase CD45 is present in two main isoforms: the large CD45RA and short CD45RO. We have recently shown that distinctive expression of these isoforms distinguishes natural killer (NK) populations. For example, co-expression both identifies vivo anti tumor NK cells hematological cancer patients. Here we show low associates with less mature, CD56bright, cells. Most healthy human donors are CD45RA+CD45RO-. CD45RA-RO+ phenotype, CD45RO cells, extremely uncommon B or...
Syndecan-1 is a proteoglycan that concentrates heparin-binding factors on the surface of multiple myeloma cells, and probably plays major role in biology. As heparan sulphate chondroitin are bioactive components syndecan-1, we analysed signature genes encoding 100 proteins involved synthesis these chains, i.e. from precursor uptake to post-translational modifications, using Affymetrix microarrays. The expression enzymes required for biosynthesis was shown increase parallel with syndecan-1...
The survival of malignant plasma cells is a key event in disease occurrence, progression and chemoresistance. Using DNA-microarrays, we analysed the expression genes coding for 58 proteins linked with extrinsic intrinsic apoptotic pathways, caspases inhibitor apoptosis proteins. We considered six memory B (MBC), seven plasmablasts (PPC), bone marrow (BMPC) purified myeloma (MMC) from 92 newly-diagnosed patients. Forty out probe sets enabled separation MBC, PPC BMPC three homogeneous...